# US 2020/0390912 A1 · Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390912 A1
- Document ID: US20200390912A1
- Status: Published application
- Kind: A1
- Application number: 16/881,182
- Filed: 2020-05-22
- Published: 2020-12-17
- Earliest claimed: 2011-11-11
- Assignees: Lantheus Medical Imaging, Inc.; Yale University
- Applicants: Lantheus Medical Imaging, Inc.; Yale University
- Inventors: Albert J. Sinusas; Joseph G. Akar; Richard R. Cesati; Heike S. Radeke; Stephen B. Haber
- Web page: https://patentgrep.com/patent/US20200390912A1

## CPC

- A61K 51/044: {having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins (rifampin A61K51/0459)}
- A61K 51/0459: {having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine}
- A61K 51/0476: {complexes from monodendate ligands, e.g. sestamibi}
- A61K 51/0478: {complexes from non-cyclic ligands, e.g. EDTA, MAG3}
- A61K 51/0497: {conjugates with a carrier being an organic compounds}
- A61K 51/08: Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins}
- A61B 2576/023: for the heart
- G16H 30/40: for processing medical images, e.g. editing
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

The invention provides, in some embodiments, methods relating to assessing increased risk of developing atrial fibrillation (AF), and/or the likelihood of responding to particular AF therapies using imaging agents comprising an MMP inhibitor linked to an imaging moiety. The invention further provides methods for evaluating the presence of the risk of developing other cardiovascular conditions and assessing the effectiveness of treatment or other intervention for such conditions by determining MMP levels.

## Claims

### Claim 1

A method of evaluating risk of developing atrial fibrillation comprising:
administering to a subject an imaging agent comprising a matrix metalloproteinase (MMP) inhibitor linked to an imaging moiety,
wherein the imaging agent comprising a matrix metalloproteinase (MMP) inhibitor linked to an imaging moiety is 99mTc-RP805:
wherein TPPTS is 3,3′,3″-Phosphanetriyltris(benzenesulfonic acid) trisodium salt, and
acquiring an image of the atria or the aortic valve region of the subject,
wherein a level of the imaging agent in the atria or aortic valve region of the subject above control is indicative of an increased risk of developing atrial fibrillation.

### Claim 2

A method for evaluating risk of developing atrial fibrillation recurrence comprising:
administering to a subject previously diagnosed with atrial fibrillation and previously treated for atrial fibrillation an imaging agent comprising a matrix metalloproteinase (MMP) inhibitor linked to an imaging moiety,
wherein the imaging agent comprising a matrix metalloproteinase (MMP) inhibitor linked to an imaging moiety is 99mTc-RP805:
wherein TPPTS is 3,3′,3″-Phosphanetriyltris(benzenesulfonic acid) trisodium salt, and
acquiring an image of the atria or the aortic valve region of the subject, wherein a level of imaging agent in the atria or aortic valve region of the subject above control is indicative of an increased risk of atrial fibrillation recurrence.

### Claim 3 (depends on 2)

The method of claim 2, wherein the atrial fibrillation recurrence is atrial fibrillation recurrence following cardioversion therapy.

### Claim 4

A method for identifying a subject having a history of atrial fibrillation that is likely to respond to treatment with an implantable pacer, pharmacological rate control therapy, pharmacological rhythm control therapy, or ablation therapy, comprising:
administering to a subject previously diagnosed with atrial fibrillation an imaging agent comprising a matrix metalloproteinase (MMP) inhibitor linked to an imaging moiety,
wherein the imaging agent comprising a matrix metalloproteinase (MMP) inhibitor linked to an imaging moiety is 99mTc-RP805:
wherein TPPTS is 3,3′,3″-Phosphanetriyltris(benzenesulfonic acid) trisodium salt; and
acquiring an image of the atria or the aortic valve region of the subject,
wherein a level of imaging agent in the atria or aortic valve region of the subject above control identifies a subject to be treated with an implantable pacer.

### Claim at position 5

5-7. (canceled)

### Claim 8 (depends on 4)

The method of claim 4, wherein the subject has experienced one AF event.

### Claim 9 (depends on 4)

The method of claim 4, wherein the subject has experienced recurrent AF.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein the image of the atria is a left atrial image.

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject is a human subject.

### Claim 13 (depends on 1)

The method of claim 1, wherein the subject does not manifest signs associated with myocardial fibrosis.

### Claim 14 (depends on 1)

The method of claim 1, wherein the subject does not manifest signs associated with myocardial remodeling.

### Claim 15 (depends on 1)

The method of claim 1, wherein the subject has experienced a myocardial infarction.

### Claim at position 14

16-17. (canceled)

### Claim 18 (depends on 1)

The method of claim 1, further comprising determining a measure of myocardial perfusion in the subject.

### Claim 19

(canceled)

### Claim 20 (depends on 4)

The method of claim 4, wherein the image of the atria is a left atrial image.

### Claim 21 (depends on 4)

The method of claim 4, wherein the subject is a human subject.

### Claim 22 (depends on 4)

The method of claim 4, wherein the subject does not manifest signs associated with myocardial fibrosis.

### Claim 23 (depends on 4)

The method of claim 4, wherein the subject does not manifest signs associated with myocardial remodeling.

### Claim 24 (depends on 4)

The method of claim 4, wherein the subject has experienced a myocardial infarction.

### Claim 25 (depends on 4)

The method of claim 4, further comprising determining a measure of myocardial perfusion in the subject.
